Patents by Inventor Manoj Maniar
Manoj Maniar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130012589Abstract: An aqueous pharmaceutical solution composition comprising between about 20 mg/ml to about 100 mg/ml of a radioprotective ?,?-unsaturated aryl sulfone, a cosolvent comprising polyethylene glycol (PEG), polypropylene glycol, polyglycerol, DMA, propylene glycol, glycerol, ethanol, sorbitol, isopropyl alcohol, or a combination thereof in an amount between about 25% and about 90% w/v, and a water soluble Vitamin E derivative, wherein the composition has a pH within the range of about 7.0 to about 9.5.Type: ApplicationFiled: March 24, 2011Publication date: January 10, 2013Applicant: ONCONOVA THERAPEUTICS, INCInventor: Manoj Maniar
-
Publication number: 20120238624Abstract: Formulations and methods are provided for the treatment of pain, and neuropathic pain in particular. The formulations are eutectic mixtures of a capsaicinoid and a local anesthetic agent and/or an anti-pruritic agent.Type: ApplicationFiled: September 14, 2011Publication date: September 20, 2012Inventor: Manoj Maniar
-
Patent number: 8063109Abstract: Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. Composition for parenteral administration are provided which comprise an effective amount of compound of formula I or a compound of formula IIa and at least about 50% by weight of at least one water soluble polymer selected from the group consisting essentially of polyethylene glycol (PEG), poly-oxyethylene, poly-oxyethylene-poly-oxypropylene copolymers, polyglycerol, polyvinylalcohol, polyvinylpyrrolidone (PVP), polyvinylpyridine N-oxide, copolymer of vinylpyridine N-oxide and vinylpyridine.Type: GrantFiled: July 15, 2005Date of Patent: November 22, 2011Assignee: Onconova Therapeutics, Inc.Inventors: Stanley C. Bell, Albert Wong, Manoj Maniar
-
Publication number: 20110028504Abstract: A pharmaceutical composition is provided for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject. An effective amount of the pharmaceutical composition provided comprising an effective amount of at least one radioprotective ?, ? unsaturated aryl sulfone, and at least one component selected from the group consisting of a) at least one water soluble polymer in an amount between about 0.5% and about 90% w/v, b) at least one chemically modified cyclodextrin in an amount between about 20% and about 60% w/v, and c) DMA in an amount between about 10% and about 50% w/v.Type: ApplicationFiled: July 28, 2006Publication date: February 3, 2011Applicant: ONCONOVA THERAPEUTICS, INC.Inventors: Manoj Maniar, Stanley C. Bell, Janice W. Bell
-
Publication number: 20100152096Abstract: Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. Composition for parenteral administration are provided which comprise an effective amount of a compound of formula I or a compound of formula IIa and at least about 50% by weight of at least one water soluble polymer selected from the group consisting essentially of polyethylene glycol (PEG), poly-oxyethylene, poly-oxyethylene-poly-oxypropylene copolymers, polyglycerol, polyvinylalcohol, polyvinylpyrrolidone (PVP), polyvinylpyridine N-oxide, copolymer of vinylpyridine N-oxide and vinylpyridine.Type: ApplicationFiled: January 16, 2008Publication date: June 17, 2010Inventors: Stanley C. Bell, Manoj Maniar
-
Publication number: 20090247624Abstract: Solution and suspension formulations are provided for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject which comprises an effective amount of at least one radioprotective ?,? unsaturated aryl sulfone wherein the composition has a pH within the range of about 8 to about 9.Type: ApplicationFiled: July 27, 2007Publication date: October 1, 2009Applicant: Onconova Therapeutics Inc.Inventors: Stanley C. Bell, Manoj Maniar
-
Publication number: 20090036462Abstract: Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. Composition for parenteral administration are provided which comprise an effective amount of compound of formula I or a compound of formula IIa and at least about 50% by weight of at least one water soluble polymer selected from the group consisting essentially of polyethylene glycol (PEG), poly-oxyethylene, poly-oxyethylene-poly-oxypropylene copolymers, polyglycerol, polyvinylalcohol, polyvinylpyrrolidone (PVP), polyvinylpyridine N-oxide, copolymer of vinylpyridine N-oxide and vinylpyridine.Type: ApplicationFiled: July 15, 2005Publication date: February 5, 2009Applicant: Onconova Therapeutics, Inc.Inventors: Stanley C. Bell, Albert Wong, Manoj Maniar
-
Publication number: 20060100272Abstract: Formulations and methods are provided for the treatment of pain, and neuropathic pain in particular. The formulations are eutectic mixtures of a capsaicinoid and a local anesthetic agent and/or an anti-pruritic agent.Type: ApplicationFiled: June 2, 2005Publication date: May 11, 2006Applicant: SRI InternationalInventor: Manoj Maniar
-
Publication number: 20060018951Abstract: The present invention provides a delivery system for the intravaginal administration of prophylactic and therapeutic agents. In one embodiment, the invention provides a pH-responsive, biocompatible film for intravaginal administration of a beneficial agent, comprising a biocompatible, hydrophilic polymer that is positively charged at a first pH and in electronically neutral form at a higher pH; an effective amount of a beneficial agent; and, optionally, at least one film-forming binder. The pH responsive film may also include other additives such as plasticizers, sustained release polymers, antioxidants, and antimicrobial agents. In another embodiment, the pH-responsive film of the present invention comprises a laminated composite of (a) a bioadhesive layer that serves to affix the film to a mucosal surface within the vagina and, laminated thereto, (b) at least one reservoir layer comprising at least one beneficial agent and a biocompatible hydrophilic polymer.Type: ApplicationFiled: August 6, 2004Publication date: January 26, 2006Applicant: SRI InternationalInventors: Manoj Maniar, Shoreh Parandoosh
-
Patent number: 5919835Abstract: Blends of polymers having properties distinct from the individual polymer components and that are suitable for use as carriers of pharmaceutically active agents, are prepared from two or more polyanhydrides, polyesters or mixtures of polyanhydrides and polyesters. The blends have different properties than the polymers used to prepare the blends, providing a means for altering the characteristics of a polymeric matrix without altering the chemical structure of the component polymers. Blends of various polyanhydrides, polyesters, and polyanhydrides and polyesters, containing pharmaceutically active agents, are prepared using solvent mixing or melt mixing procedures.Type: GrantFiled: December 23, 1992Date of Patent: July 6, 1999Assignee: Massachusetts Institute of TechnologyInventors: Abraham J. Domb, Manoj Maniar, Andrew S. T. Haffer
-
Patent number: 5846525Abstract: The present invention provides a composition comprising an ion exchange resin and a therapeutically active biopolymer in a form for oral administration. The present invention also provides a composition comprising Amberlite.RTM. IRP-64 and a cytokine regulatory agent having the amino acid sequence:Ac-Nle-Gln-His-(D)Phe-Arg-(D)Trp-Gly-NH.sub.2,in a form for oral administration. The present invention further provides a method of protecting a therapeutically active biopolymer from degradation by forming a complex of the biopolymer and an ion exchange resin. In addition, the present invention provides a method of reducing or inhibiting the severity of a pathological condition by orally administering a therapeutically effective dose of the composition.Type: GrantFiled: December 19, 1995Date of Patent: December 8, 1998Assignee: Trega Biosciences, Inc.Inventors: Manoj Maniar, Steven Mauch
-
Patent number: 5512055Abstract: Devices are provided having a polymer coating incorporating compounds inhibiting inflammation and infection, along with subsequent tissue growth onto and around the device. Preferred embodiments include catheters, tubes, and implants that abut tissue following implantation into the body, especially for use in the naso-oto-pharyngeal areas of the body, where localized chronic infection/inflammation of the tissues surrounding the implant may be decreased by sustained release of antibiotics, antifungals, antivirals, anti-inflammatories, and other compounds, such as anticoagulants and anesthetics. Preferred polymeric coatings are thin, well adhered to the underlying device, and formed of a biocompatible, non-bioerodible polymer such as polyurethane or ethylene vinyl acetate. The drug is incorporated either by solvent casting or by absorption into the solidified polymer. The drug incorporated polymer can also be used to form devices, or portions of devices, for implantation.Type: GrantFiled: September 30, 1994Date of Patent: April 30, 1996Assignee: Leonard BloomInventors: Abraham J. Domb, Alain Shikani, Andrew S. T. Haffer, Manoj Maniar
-
Patent number: 5482927Abstract: An improved surface erodible controlled release composition and the manufacturing thereof, for the continuous administration of biologically active proteins or peptide fragments, is described. The biologically active protein is dissolved in water or a suitable solvent, alone or in combination with stabilizing agents. The solution is either lyophilized or spray dried to obtain a free flowing powder. The powder is then sieved to obtain the desired average particle size. The free flowing powder of the protein or the stabilized protein is then incorporated into a biodegradable matrix formed of fatty acid anhydride, fatty acid and/or a salt thereof. Examples using growth hormone and bovine serum albumin demonstrate enhanced release, stability and controlled release properties for the fatty acid anhydride microparticular system.Type: GrantFiled: February 23, 1994Date of Patent: January 9, 1996Assignee: Massachusetts Institute of TechnologyInventors: Manoj Maniar, Abraham J. Domb
-
Patent number: 5317079Abstract: Fatty acid terminated polyanhydrides suitable for use as controlled release matrices in biodegradable sustained release drug delivery systems and methods for making thereof are described. The polymers are more soluble in organic solvents, and have a lower melting point than the corresponding non-fatty acid terminated polyanhydrides. The fatty acid terminated polyanhydrides are also more hydrophobic than the corresponding polyanhydrides that are not terminated with a fatty acid, and combine the properties of thermodynamic and hydrolytic stability, and easy storage. The polymers can be produced with a controlled and low molecular weight. The polyanhydrides are useful in a number of applications, including as a matrix in biodegradable drug delivery systems.Type: GrantFiled: September 18, 1992Date of Patent: May 31, 1994Assignee: Nova Pharmaceutical CorporationInventors: Abraham J. Domb, Manoj Maniar
-
Patent number: 5240963Abstract: Branched polyanhydrides that have superior properties for use in the controlled delivery of substances, prepared by the polymerization of a dicarboxylic acid monomer and a branching agent. The branching agent is a polycarboxylic acid monomer such as 1,3,5-benzenetricarboxylic acid ("BTC"), or an oligomerized fatty acid trimer. Alternatively, the branching agent is a polycarboxylic acid polymer such as poly(acrylic acid) ("PAA"). These branched polymers have significantly higher molecular weights and lower specific viscosity than linear polymers prepared under similar conditions. A major advantage of branched polyanhydrides is that the degradation and release kinetics can be substantially altered without significantly changing the physical properties of the polymer relative to the corresponding linear polymer. By manipulating both the diacid and the branching agent, a wide variety of biodegradable controlled delivery devices for diverse applications can be prepared.Type: GrantFiled: September 18, 1992Date of Patent: August 31, 1993Assignee: Nova Pharmaceutical CorporationInventors: Abraham J. Domb, Manoj Maniar
-
Patent number: 5227165Abstract: A local anesthetic microsuspension system is disclosed that includes lipospheres, that are solid, water-insoluble microparticles that have a layer of a phospholipid embedded on their surface. The core of the liposphere is a solid anesthetic such as lidocaine or marcaine, or an anesthetic dispersed in an inert solid vehicle, such as a wax. Anesthetic lipospheres provide a controlled delivery of local anesthetics to achieve extended, effective relief from pain by slowly releasing the anesthetic from the solid hydrophobic core. This is highly preferred over the situation in which an aqueous solution of local anesthetic must be frequently administered because it is quickly systemically absorbed.Type: GrantFiled: January 22, 1992Date of Patent: July 13, 1993Assignee: Nova Pharmaceutical CorporationInventors: Abraham J. Domb, Manoj Maniar
-
Patent number: 5179189Abstract: Fatty acid terminated polyanhydrides suitable for use as controlled release matrices in biodegradable sustained release drug delivery systems and methods for making thereof are described. The polymers are more soluble in organic solvents, and have a lower melting point than the corresponding non-fatty acid terminated polyanhydrides. The fatty acid terminated polyanhydrides are also more hydrophobic than the corresponding polyanhydrides that are not terminated with a fatty acid, and combine the properties of thermodynamic and hydrolytic stability, and easy storage. The polymers can be produced with a controlled and low molecular weight. The polyanhydrides are useful in a number of applications, including as a matrix in biodegradable drug delivery systems.Type: GrantFiled: September 9, 1991Date of Patent: January 12, 1993Assignee: Nova Pharmaceutical CorporationInventors: Abraham J. Domb, Manoj Maniar
-
Patent number: 5175235Abstract: Branched polyanhydrides that have superior properties for use in the controlled delivery of substances, prepared by the polymerization of a dicarboxylic acid monomer and a branching agent. The branching agent is a polycarboxylic acid monomer such as 1,3,5-benzenetricarboxylic acid ("BTC"), or an oligomerized fatty acid trimer. Alternatively, the branching agent is a polycarboxylic acid polymer such as poly(acrylic acid) ("PAA"). These branched polymers have significantly higher molecular weights and lower specific viscosity than linear polymers prepared under similar conditions. A major advantage of branched polyanhydrides is that the degradation and release kinetics can be substantially altered without significantly changing the physical properties of the polymer relative to the corresponding linear polymer. By manipulating both the diacid and the branching agent, a wide variety of biodegradable controlled delivery devices for diverse applications can be prepared.Type: GrantFiled: June 4, 1990Date of Patent: December 29, 1992Assignee: Nova Pharmaceutical CorporationInventors: Abraham J. Domb, Manoj Maniar